Clinical trials sometimes measure a surrogate endpoint, such as a biomarker, before effects on survival or symptoms can be observed. Some surrogates are well validated because changes reliably predict patient benefit; others have improved while the treatment produced no meaningful clinical gain or caused offsetting harms. Validation is disease- and treatment-specific.